Divestiture and Equity-Method Investments Equity-Method Investments (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended						3 Months Ended					3 Months Ended
	Mar. 30, 2014		Mar. 31, 2013		Mar. 31, 2013 Hisun Pfizer Pharmaceuticals Co. Ltd [Member]	Sep. 06, 2012 Hisun Pfizer Pharmaceuticals Co. Ltd [Member]	Mar. 30, 2014 ViiV Healthcare Limited [Member]	Mar. 30, 2014 Glaxosmithkline plc [Member] ViiV Healthcare Limited [Member]	Sep. 06, 2012 Zhejiang Hisun [Member] Hisun Pfizer Pharmaceuticals Co. Ltd [Member]	Apr. 01, 2014 Equity Method Investments [Member] ViiV Healthcare Limited [Member]	Apr. 01, 2014 Equity Method Investments [Member] Glaxosmithkline plc [Member] ViiV Healthcare Limited [Member]	Mar. 31, 2013 Indirect retained Interest [Member] Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Schedule of Equity Method Investments [Line Items]
(Gain) loss associated with the transfer of certain product rights to an equity-method investment	$ 0	[1]	$ (490)	[1]	$ 490							$ 240
Equity method investment, ownership percentage					49.00%	49.00%	12.60%	77.40%	51.00%	11.70%	78.30%
Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee							$ 36

[1] Represents the gain associated with the transfer of certain product rights to Hisun Pfizer, our 49%-owned equity-method investment in China. For additional information, see Note 2B. Divestiture and Equity-Method Investments: Equity-Method Investments.